Insulin-releasing and metabolic effects of small molecule GLP-1 receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline

European Journal of Pharmacology

Volumn 628, Issue 1-3, 2010, Pages 268-273

  Irwin, Nigel ^a   Flatt, Peter R ^a   Patterson, Steven ^a   Green, Brian D ^b  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Diabetes; Glucagon like peptide 1 (GLP 1); Glucose homeostasis; Insulin secretion; Small molecule

Indexed keywords

6,7 DICHLORO 2 METHYLSULFONYL 3 N TERT BUTYLAMINOQUINOXALINE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; LIRAGLUTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG STRUCTURE; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; INSULIN LIKE ACTIVITY; INSULIN RELEASE; MOLECULAR WEIGHT; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BIOMIMETIC MATERIALS; BLOOD GLUCOSE; CELL LINE; GLUCAGON-LIKE PEPTIDE 1; HYPOGLYCEMIC AGENTS; INSULIN; MICE; MOLECULAR WEIGHT; PEPTIDES; QUINOXALINES; RECEPTORS, GLUCAGON; SULFONES; VENOMS;

EID: 73649135313     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.11.022     Document Type: Article

References (16)

1. Baggio L.L., and Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 132 (2007) 2131-2157
2. Bailey C.J., Flatt P.R., and Atkins T.W. Influence of genetic background and age on the expression of the obese hyperglycaemic syndrome in Aston ob/ob mice. Int. J. Obes. 6 (1982) 11-21
3. Chen D., Liao J., Li N., Zhou C., Liu Q., Wang G., Zhang R., Zhang S., Lin L., Chen K., Xie X., Nan F., Young A.A., and Wang M.W. A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 943-948
4. 2+) influx. J. Endocrinol. 201 (2009) 361-367
5. Flatt P.R., and Bailey C.J. Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice. Diabetologia 20 (1981) 573-577
6. Flatt P.R., Bailey C.J., and Green B.D. Recent advances in antidiabetic drug therapies targeting the enteroinsular axis. Curr. Drug. Metab. 10 (2009) 125-137
7. 13)GIP. Cell Biol. Int. 27 (2003) 41-46
8. Irwin N., McClean P.L., Hunter K., and Flatt P.R. Metabolic effects of sustained activation of the GLP-1 receptor alone and in combination with background GIP receptor antagonism in high fat-fed mice. Diabetes Obes. Metab. 11 (2009) 603-610
9. Kendall D.M., Riddle M.C., Rosenstock J., Zhuang D., Kim D.D., Fineman M.S., and Baron A.D. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28 (2005) 1083-1091
10. Knudsen L.B., Kiel D., Teng M., Behrens C., Bhumralkar D., Kodra J.T., Holst J.J., Jeppesen C.B., Johnson M.D., de Jong J.C., Jorgensen A.S., Kercher T., Kostrowicki J., Madsen P., Olesen P.H., Petersen J.S., Poulsen F., Sidelmann U.G., Sturis J., Truesdale L., May J., and Lau J. Small-molecule agonists for the glucagon-like peptide 1 receptor. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 937-942
11. McClenaghan N.H., Barnett C.R., Ah-Sing E., Abdel-Wahab Y.H., O'Harte F.P., Yoon T.W., Swanston-Flatt S.K., and Flatt P.R. Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion. Diabetes 45 (1996) 1132-1140
12. Teng M., Johnson M.D., Thomas C., Kiel D., Lakis J.N., Kercher T., Aytes S., Kostrowicki J., Bhumralkar D., Truesdale L., May J., Sidelman U., Kodra J.T., Jørgensen A.S., Olesen P.H., de Jong J.C., Madsen P., Behrens C., Pettersson I., Knudsen L.B., Holst J.J., and Lau J. Small molecule ago-allosteric modulators of the human glucagon-like peptide-1 (hGLP-1) receptor. Bioorg. Med. Chem. Lett. 17 (2007) 5472-5478
13. Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 8641-8645
14. Tibaduiza E.C., Chen C., and Beinborn M. A small molecule ligand of the glucagon-like peptide 1 receptor targets its amino-terminal hormone binding domain. J. Biol. Chem. 276 (2001) 37787-37793
15. Toft-Nielsen M.B., Damholt M.B., Madsbad S., Hilsted L.M., Hughes T.E., Michelsen B.K., and Holst J.J. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J. Clin. Endocrinol. Metab. 86 (2001) 3717-3723
16. Tolhurst G., Reimann F., and Gribble F.M. Nutritional regulation of glucagon-like peptide-1 secretion. J. Physiol. 587 (2009) 27-32